Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$460.00 USD
-4.92 (-1.06%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $460.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$460.00 USD
-4.92 (-1.06%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $460.01 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Zacks News
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
by Zacks Equity Research
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $397.70, moving -0.76% from the previous trading session.
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
by Zacks Equity Research
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies
by Zacks Equity Research
Vertex (VRTX) signs a collaboration agreement with TreeFrog to utilize the latter's C-Stem technology in order to optimize the production of its T1D cell therapies.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $394.28, indicating a +0.2% shift from the previous trading day.
Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug
by Zacks Equity Research
Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024.
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $394.17 in the latest trading session, marking a -0.8% move from the prior day.
bluebird (BLUE) Underperforms Industry YTD Amid Challenges
by Zacks Equity Research
bluebird (BLUE) plunges 25% year to date as it struggles to fuel the growth of its complex and expensive gene therapies.
Is Vertex (VRTX) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex
by Zacks Equity Research
Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) reachead $397.58 at the closing of the latest trading day, reflecting a -1.71% change compared to its last close.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Vertex (VRTX) Moves Kidney Disease Drug to Phase 3 Development
by Zacks Equity Research
Vertex (VRTX) advances inaxaplin to late-stage development. It will evaluate the drug in lower age groups and will enroll patients aged 10 years and older with APOL1-mediated kidney disease.
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $420.48, denoting a +0.59% change from the preceding trading day.
Brokers Suggest Investing in Vertex (VRTX): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
by Zacks Equity Research
bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day.
Vertex (VRTX) Continues to Diversify Beyond CF Franchise
by Zacks Equity Research
While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month.
bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up
by Zacks Equity Research
bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $411.38, denoting a +0.91% change from the preceding trading day.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE